Literature DB >> 27989923

A robust vitronectin-derived peptide for the scalable long-term expansion and neuronal differentiation of human pluripotent stem cell (hPSC)-derived neural progenitor cells (hNPCs).

Divya Varun1, Gayathri Rajaram Srinivasan1, Yi-Huan Tsai1, Hyun-Je Kim1, Joshua Cutts1, Francis Petty1, Ryan Merkley2, Nicholas Stephanopoulos2, Dasa Dolezalova3, Martin Marsala4, David A Brafman5.   

Abstract

Despite therapeutic advances, neurodegenerative diseases and disorders remain some of the leading causes of mortality and morbidity in the United States. Therefore, cell-based therapies to replace lost or damaged neurons and supporting cells of the central nervous system (CNS) are of great therapeutic interest. To that end, human pluripotent stem cell (hPSC) derived neural progenitor cells (hNPCs) and their neuronal derivatives could provide the cellular 'raw material' needed for regenerative medicine therapies for a variety of CNS disorders. In addition, hNPCs derived from patient-specific hPSCs could be used to elucidate the underlying mechanisms of neurodegenerative diseases and identify potential drug candidates. However, the scientific and clinical application of hNPCs requires the development of robust, defined, and scalable substrates for their long-term expansion and neuronal differentiation. In this study, we rationally designed a vitronectin-derived peptide (VDP) that served as an adhesive growth substrate for the long-term expansion of several hNPC lines. Moreover, VDP-coated surfaces allowed for the directed neuronal differentiation of hNPC at levels similar to cells differentiated on traditional extracellular matrix protein-based substrates. Overall, the ability of VDP to support the long-term expansion and directed neuronal differentiation of hNPCs will significantly advance the future translational application of these cells in treating injuries, disorders, and diseases of the CNS.
Copyright © 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Defined conditions; Human neural progenitor cells; Human pluripotent stem cells; Peptide

Mesh:

Substances:

Year:  2016        PMID: 27989923      PMCID: PMC5235981          DOI: 10.1016/j.actbio.2016.10.037

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  78 in total

1.  EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells.

Authors:  Fiona Doetsch; Leopoldo Petreanu; Isabelle Caille; Jose Manuel Garcia-Verdugo; Arturo Alvarez-Buylla
Journal:  Neuron       Date:  2002-12-19       Impact factor: 17.173

2.  Cell type-specific differences in glycosaminoglycans modulate the biological activity of a heparin-binding peptide (RKRLQVQLSIRT) from the G domain of the laminin alpha1 chain.

Authors:  M P Hoffman; J A Engbring; P K Nielsen; J Vargas; Z Steinberg; A J Karmand; M Nomizu; Y Yamada; H K Kleinman
Journal:  J Biol Chem       Date:  2001-04-13       Impact factor: 5.157

Review 3.  Investigating human disease using stem cell models.

Authors:  Jared L Sterneckert; Peter Reinhardt; Hans R Schöler
Journal:  Nat Rev Genet       Date:  2014-07-29       Impact factor: 53.242

Review 4.  Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor.

Authors:  Soo-Hyun Kim; Jeremy Turnbull; Scott Guimond
Journal:  J Endocrinol       Date:  2011-02-09       Impact factor: 4.286

5.  Differentiation of oligodendrocyte progenitor cells from human embryonic stem cells on vitronectin-derived synthetic peptide acrylate surface.

Authors:  Yan Li; Archna Gautam; Jiwei Yang; Liqun Qiu; Zara Melkoumian; Jennifer Weber; Lavanya Telukuntla; Rashi Srivastava; Erik M Whiteley; Ralph Brandenberger
Journal:  Stem Cells Dev       Date:  2013-02-13       Impact factor: 3.272

6.  Generation and differentiation of neurospheres from murine embryonic day 14 central nervous system tissue.

Authors:  Sharon A Louis; Brent A Reynolds
Journal:  Methods Mol Biol       Date:  2005

Review 7.  Role of E-cadherin and other cell adhesion molecules in survival and differentiation of human pluripotent stem cells.

Authors:  Li Li; Steffany A L Bennett; Lisheng Wang
Journal:  Cell Adh Migr       Date:  2012 Jan-Feb       Impact factor: 3.405

8.  A novel synthetic peptide from the B1 chain of laminin with heparin-binding and cell adhesion-promoting activities.

Authors:  A S Charonis; A P Skubitz; G G Koliakos; L A Reger; J Dege; A M Vogel; R Wohlhueter; L T Furcht
Journal:  J Cell Biol       Date:  1988-09       Impact factor: 10.539

Review 9.  Neural stem cells: ready for therapeutic applications?

Authors:  Simona Casarosa; Yuri Bozzi; Luciano Conti
Journal:  Mol Cell Ther       Date:  2014-10-15

10.  β1-Integrin and integrin linked kinase regulate astrocytic differentiation of neural stem cells.

Authors:  Liuliu Pan; Hilary A North; Vibhu Sahni; Su Ji Jeong; Tammy L Mcguire; Eric J Berns; Samuel I Stupp; John A Kessler
Journal:  PLoS One       Date:  2014-08-06       Impact factor: 3.240

View more
  4 in total

1.  An integrated biomanufacturing platform for the large-scale expansion and neuronal differentiation of human pluripotent stem cell-derived neural progenitor cells.

Authors:  Gayathri Srinivasan; Daylin Morgan; Divya Varun; Nicholas Brookhouser; David A Brafman
Journal:  Acta Biomater       Date:  2018-05-15       Impact factor: 8.947

2.  A Defined and Scalable Peptide-Based Platform for the Generation of Human Pluripotent Stem Cell-Derived Astrocytes.

Authors:  Sreedevi Raman; Gayathri Srinivasan; Nicholas Brookhouser; Toan Nguyen; Tanner Henson; Daylin Morgan; Joshua Cutts; David A Brafman
Journal:  ACS Biomater Sci Eng       Date:  2020-05-06

3.  A microcarrier-based protocol for scalable generation and purification of human induced pluripotent stem cell-derived neurons and astrocytes.

Authors:  Jacob Knittel; Gayathri Srinivasan; Carlye Frisch; Nicholas Brookhouser; Sreedevi Raman; Albert Essuman; David A Brafman
Journal:  STAR Protoc       Date:  2022-08-18

4.  APOE2 mitigates disease-related phenotypes in an isogenic hiPSC-based model of Alzheimer's disease.

Authors:  Nicholas Brookhouser; Sreedevi Raman; Carlye Frisch; Gayathri Srinivasan; David A Brafman
Journal:  Mol Psychiatry       Date:  2021-04-09       Impact factor: 15.992

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.